Fas	O
-	O
Fas	O
ligand	O
signaling	O
pathway	O
mediates	O
an	O
interleukin	O
-	O
12	O
-	O
induced	O
rejection	O
of	O
a	O
murine	O
prostate	B-Cancer
tumor	I-Cancer
system	O
.	O

BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
anti	O
-	O
tumor	B-Cancer
activities	O
of	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
involve	O
the	O
induction	O
of	O
apoptosis	O
.	O

Fas	O
(	O
APO	O
-	O
1	O
/	O
CD95	O
)	O
is	O
a	O
type	O
I	O
membrane	B-Cellular_component
protein	O
that	O
is	O
capable	O
of	O
initiating	O
an	O
apoptosis	O
signaling	O
pathway	O
when	O
bound	O
to	O
its	O
ligand	O
(	O
FasL	O
)	O
.	O

We	O
undertook	O
this	O
study	O
to	O
test	O
the	O
hypothesis	O
that	O
Fas	O
-	O
FasL	O
-	O
mediated	O
apoptosis	O
plays	O
a	O
role	O
in	O
IL	O
-	O
12	O
-	O
induced	O
tumor	B-Cancer
regression	O
.	O

METHODS	O
:	O
An	O
mIL	O
-	O
12	O
expression	O
vector	O
driven	O
by	O
cytomegalovirus	O
promoter	O
was	O
used	O
to	O
express	O
murine	O
IL	O
-	O
12	O
cDNA	O
in	O
the	O
RM	B-Cell
-	I-Cell
9	I-Cell
murine	I-Cell
prostate	I-Cell
carcinoma	I-Cell
cell	I-Cell
line	I-Cell
.	O

Control	O
RM	B-Cell
-	I-Cell
9	I-Cell
cells	I-Cell
and	O
RM	B-Cell
-	I-Cell
9	I-Cell
cells	I-Cell
stably	O
transfected	O
with	O
IL	O
-	O
12	O
gene	O
(	O
RM	B-Cell
-	I-Cell
9	I-Cell
-	I-Cell
IL12	I-Cell
)	O
were	O
inoculated	O
subcutaneously	B-Immaterial_anatomical_entity
in	O
4	O
-	O
to	O
6	O
-	O
week	O
-	O
old	O
male	O
C57BL	O
/	O
J6	O
mice	O
.	O

Tumor	B-Cancer
size	O
was	O
measured	O
every	O
3	O
days	O
.	O

Western	O
blot	O
and	O
immunohistochemical	O
assays	O
were	O
used	O
to	O
evaluate	O
Fas	O
and	O
FasL	O
protein	O
expression	O
.	O

In	O
situ	O
fluorescent	O
end	O
labeling	O
was	O
used	O
to	O
label	O
apoptotic	O
cells	B-Cell
.	O

RESULTS	O
:	O
IL	O
-	O
12	O
-	O
expressing	O
RM	B-Cell
-	I-Cell
9	I-Cell
prostate	I-Cell
carcinoma	I-Cell
cells	I-Cell
transplanted	O
into	O
C57BL	O
/	O
J6	O
mice	O
grew	O
more	O
slowly	O
than	O
control	O
RM	B-Cell
-	I-Cell
9	I-Cell
cells	I-Cell
and	O
vector	O
control	O
RM	B-Cell
-	I-Cell
9	I-Cell
-	I-Cell
Luc	I-Cell
cells	I-Cell
.	O

The	O
average	O
survival	O
time	O
of	O
the	O
RM	B-Cell
-	I-Cell
9	I-Cell
-	I-Cell
IL12	I-Cell
mice	O
was	O
longer	O
than	O
53	O
days	O
,	O
whereas	O
the	O
mean	O
survival	O
for	O
mice	O
transplanted	O
with	O
control	O
RM	B-Cell
-	I-Cell
9	I-Cell
cells	I-Cell
was	O
only	O
16	O
days	O
.	O

Apoptotic	O
cells	B-Cell
were	O
more	O
numerous	O
in	O
RM	B-Cancer
-	I-Cancer
9	I-Cancer
-	I-Cancer
IL12	I-Cancer
tumors	I-Cancer
:	O
10	O
.	O
3	O
%	O
vs	O
.	O
1	O
.	O
5	O
%	O
in	O
control	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Fas	O
and	O
FasL	O
proteins	O
were	O
increased	O
approximately	O
twofold	O
in	O
the	O
RM	B-Cancer
-	I-Cancer
9	I-Cancer
-	I-Cancer
IL12	I-Cancer
tumors	I-Cancer
compared	O
with	O
the	O
RM	B-Cancer
-	I-Cancer
9	I-Cancer
control	I-Cancer
tumors	I-Cancer
as	O
determined	O
by	O
Western	O
blot	O
and	O
immunohistochemical	O
analyses	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
Fas	O
-	O
FasL	O
-	O
mediated	O
apoptosis	O
pathway	O
may	O
contribute	O
to	O
the	O
IL	O
-	O
12	O
-	O
induced	O
rejection	O
of	O
prostate	B-Cancer
carcinoma	I-Cancer
.	O

